Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Investigate the Safety, Tolerability, PK and PD of MG1113 in Healthy Subjects and Hemophilia Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03855696
Recruitment Status : Completed
First Posted : February 27, 2019
Last Update Posted : October 26, 2021
Sponsor:
Collaborator:
Dream CIS, Inc.
Information provided by (Responsible Party):
Green Cross Corporation

Brief Summary:
The purpose of this study is to assess the safety and tolerability of MG1113 in the single ascending dose study (IV injection or SC injection) in healthy subjects and hemophiia patients.

Condition or disease Intervention/treatment Phase
Hemophilia Biological: MG1113 Other: Placebo of MG1113 Phase 1

Detailed Description:

This is a single-dose study that explore the safety, tolerability, PK, and PD of the study drug by sequentially increasing the study drug in 4 dose levels. The route of administration is either subcutaneous (SC) injection or intravenous (IV) injection.

For healthy subjects, 6 subjects will be assigned to the study group and 2 subjects will be assigned to the placebo group to explore the safety and tolerability, and PK/PD of the study drug in comparison with placebo. Hemophilia patients will be assigned only to the study group with 3 and 6 subjects in each cohort, respectively.

The investigator and subjects will know which cohort the healthy subjects have been assigned to, but they will be double-blinded as to whether the subjects are assigned to the study group (study drug) or the placebo group (placebo) within each cohort.

The doses planned in healthy subjects are 0.5 mg/kg, 1.7 mg/kg, and 3.3 mg/kg by SC injection; 3.3 mg/kg by IV injection. In hemophilia patients, 1.7 mg/kg and 3.3 mg/kg will be administered by SC injection. The planned dose will be administered after checking the safety and tolerability at the previous dose to the extent not exceeding the criteria for discontinuation of dose escalation. The dose escalation will be decided by the Data Monitoring Committee(DMC) and Data and Safety Monitoring Boards (DSMB) in the blinded evaluation of the safety and tolerability data obtained from each previous cohort for 7 days after administration. Before deciding dose escalation and proceeding to the next step, the safety, tolerability, PK, and PD data obtained from all healty subjects and hemophilia patients up to cohort 6 will be evaluated by the Data and Safety Monitoring Boards (DSMB) in an unblinded manner. In addition, if necessary, the analysis result of cohort that has completed all the scheduled visits can be reviewed in an unblinded manner.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 41 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Sequential dose escalation model
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Phase I, Randomized, Double-blind, Placebo-Controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MG1113 in Healthy Subjects and Hemophilia Patients
Actual Study Start Date : January 21, 2019
Actual Primary Completion Date : June 30, 2021
Actual Study Completion Date : August 31, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: MG1113
  • Anti-tissue factor pathway inhibitor (TFPI) recombinant antibody
  • Each vial contains 1mL of study drug
  • The doses planned in healthy subjects are 0.5 mg/kg, 1.7 mg/kg, and 3.3 mg/kg by SC injection; 3.3 mg/kg by IV injection. In hemophilia patients, 1.7 mg/kg and 3.3 mg/kg will be administered by SC injection.
Biological: MG1113
MG1113

Placebo Comparator: Placebo of MG1113
  • Placebo of MG1113
  • Each vial contains 1mL of study drug
Other: Placebo of MG1113
Placebo of MG1113




Primary Outcome Measures :
  1. Adverse events [ Time Frame: Through study completion (~50 day) ]
    Adverse events such as subjective and objective symptoms


Secondary Outcome Measures :
  1. Immunogenicity assay [ Time Frame: Through study completion (~50 day) ]
    ADA [Anti-Drug Ab]

  2. Pharmacokinetic assessment - Cmax [ Time Frame: Through study completion (~50 day) ]
    Cmax

  3. Pharmacokinetic assessment - Tmax [ Time Frame: Through study completion (~50 day) ]
    Tmax

  4. Pharmacokinetic assessment - AUClast [ Time Frame: Through study completion (~50 day) ]
    AUClast

  5. Pharmacokinetic assessment - AUCinf [ Time Frame: Through study completion (~50 day) ]
    AUCinf

  6. Pharmacokinetic assessment - half-life [ Time Frame: Through study completion (~50 day) ]
    half-life

  7. Pharmacokinetic assessment - CL/F (for SC) [ Time Frame: Through study completion (~50 day) ]
    CL/F (for SC)

  8. Pharmacokinetic assessment - CL (for IV) [ Time Frame: Through study completion (~50 day) ]
    CL (for IV)

  9. Pharmacokinetic assessment - Vd/F (for SC) [ Time Frame: Through study completion (~50 day) ]
    Vd/F (for SC)

  10. Pharmacokinetic assessment - Vd (for IV) [ Time Frame: Through study completion (~50 day) ]
    Vd (for IV)

  11. Pharmacokinetic assessment - Bioavailability (F) [ Time Frame: Through study completion (~50 day) ]
    Bioavailability (F) Bioavailability (F) = AUCinf (at SC dosing [3.3 mg/kg])/AUCinf (at IV dosing [3.3 mg/kg])

  12. Pharmacodynamic assessment - Free TFPI in plasma [ Time Frame: Through study completion (~50 day) ]
    Free TFPI in plasma (ng/mL)

  13. Pharmacodynamic assessment - Diluted PT [ Time Frame: Through study completion (~50 day) ]
    Diluted PT (sec)

  14. Pharmacodynamic assessment - residual TFPI activity [ Time Frame: Through study completion (~50 day) ]
    residual TFPI activity

  15. Pharmacodynamic assessment - Thrombin generation [ Time Frame: Through study completion (~50 day) ]
    Thrombin generation (lag time, peak generation, Endogenous thrombin generation potential [ETP])

  16. Pharmacodynamic assessment - Pro-coagulant effect [ Time Frame: Through study completion (~50 day) ]
    Pro-coagulant effect (D-dimer, Fibrinogen, prothrombin fragments 1+2)

  17. Physical examination [ Time Frame: Through study completion (~50 day) ]
    Physical examination

  18. Incidence of participant abnormalities in 12-lead ECG (Ventricular rate in beat/min, Interval for PR in msec, QRS in msec, QTc in msec) for physiological parameter [ Time Frame: Through study completion (~50 day) ]

    The result for 12-lead ECG will be reported as Clinical Significant or Not-Clinical Significant.

    • Ventricular rate in beat/min
    • Interval for PR in msec
    • QRS in msec
    • QTc in msec

  19. Vital signs - blood pressure (Systolic, Diastolic) [ Time Frame: Through study completion (~50 day) ]
    Vital signs - blood pressure (Systolic, Diastolic)

  20. Vital signs - pulse rate [ Time Frame: Through study completion (~50 day) ]
    Vital signs - pulse rate

  21. Vital signs - body temperature [ Time Frame: Through study completion (~50 day) ]
    Vital signs - body temperature

  22. Frequency of Bleeding (only for hemophilia patients) [ Time Frame: Through study completion (~50 day) ]
    Bleeding evaluation (only for hemophilia patients) by questionnaire; Occurrence date, Persistence in yes or no questionnaire, Causes (blood in naturally occurring/Traumatic bleeding), Severity (mild/moderate/Severe)

  23. Local reaction in injection site [ Time Frame: Through study completion (~50 day) ]

    Pain or tenderness, itching, rash, redness (in mm), and induration (in mm) will be reported.

    Local stimulation test in injection site: Occurrence date, Persistence, Causes, Severity (mild/moderate/Severe) The occurrence of pain or tenderness, itching and rash will be reported by Yes or No questionnaire.

    The size of redness and induration will be measured in millmeters(mm).


  24. Incidence of participant abnormalities in laboratory tests by physiological parameter (Hematology, clinical chemistry, urinalysis, and blood coagulation test) [ Time Frame: Through study completion (~50 day) ]
    Parameters for laboratory tests include Hematology(WBC in 10**3/mcL,Neutrophils in %,ANC in mcL,Lymphosyte in %,Monocyte in %,Eosinophils in %,Basophils in %,RBC in 10**6/mcL,Hemoglobin in g/dL,Hematocrit in %,MCV in fL, MCH in pg,MCHC in g/dL,Platelets in 10**3/mcL,MPV in fL),Clinical chemistry(Glucose in mg/dL,BUN in mg/dL,Uric adic in mg/dL,Total cholesterol in mg/dL,Triglyceride in mg/dL,Protein,Albumin in g/dL,Total bilirubin in mg/dL,Alkaline phosphatase in IU/L,AST in IU/L,ALT in IU/L,r-GT in IU/L,LDH in IU/L,Serum creatinine in mg/dL,Na in mmol/L,K in mmol/L,Cl in mmol/L,CPK in IU/L,Troponin I in ng/mL,Troponin T in ng/mL,Creatinine Clearance),Urinalysis(These values are reported only as a number;Specific garavity,Color,pH,Protein,Glucose,Ketone,Bilirubin,Blood,Urobilinogen,Nitrite,WBC,Squma EP cell,Casts,Crystal,Clarity,RBC),Blood coagulation test (aPTT in sec,PT in sec,Fibronogen in mg/dL,Antithrombon III in %,Protein C in %,Protein S in%)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

<Healthy adult subjects>

  • Inclusion Criteria:

    1. Healthy male adult subjects aged 19-60 years (both inclusive) at screening
    2. 50 to 90 kg in weight with calculated BMI between 18.5 and 29.9 kg/m2
    3. Agree to use medically acceptable adequate dual contraceptive methods (condom, vasectomy, spermicide, oral contraceptives, intrauterine device, and complete sexual abstinence, etc.) and not to donate sperm until 3 months after administration of the investigational product
    4. Voluntarily decided to participate in the study and provided written consent to follow precautions after receiving a detailed explanation on this study and fully understanding the information
  • Exclusion Criteria:

    1. Presence or history of clinically significant cardiovascular, respiratory, hepatic, renal, hematologic, gastrointestinal, endocrine, immune, skin, nervous, or psychiatric disease
    2. Symptoms of acute disease within 28 days of investigational product administration
    3. Medical history that may affect absorption, distribution, metabolism and excretion of drugs
    4. Clinically significant active chronic disease
    5. Clinically significant allergic disease (however, mild allergic rhinitis or allergic dermatitis not requiring any medication is allowed) or history of any anaphylactic reaction
    6. Any of the following results from laboratory tests: 1) AST (sGOT) or ALT (sGPT) >2 x UNL 2) Hb < 9.0 g/dL 3) Absolute Neutrophil Count < 1500 mm2 4) Platelet count < 100 x 103 mm2 5) aPTT, PT > 1.5 x UNL 6) Have hepatitis B (HBsAg positive) or C (anti-HCV positive), or have positive HIV test result 7) Creatinine clearance ≤80 mL/min (calculated by the Cockcroft-Gault formula)
    7. Have a family history or be considered to be at risk of thromboembolic events, or have the following test results: 1) Antithrombin level ≤LNL 2) Protein C or S activity ≤LNL 3) Factor V Leiden mutation 4) Prothrombin G20210A mutation
    8. Used ethical drugs including prescription drugs within 14 days of investigational product administration
    9. Used drugs (over-the-counter drugs, herbal medicines, and nutritional agents and vitamins for the purpose of same efficacy) within 7 days of investigational product administration
    10. Cannot have standard meals provided at the hospital
    11. Donated whole blood within 60 days of investigational product administration, or donated blood components within 20 days of investigational product administration, or received blood transfusion within 1 month before administration
    12. Participated in another clinical trial or bioequivalence study within 90 days of investigational product administration (If participating in a clinical trial after 12/06/2019, not within 90 days, but within 6 months is applied)
    13. Individuals who consume caffeine (caffeine >5 cups/day) or alcohol (alcohol >30 g/day) continuously, who cannot abstain from drinking during the study, or heavy smoker (>10 cigarettes/day)
    14. Determined to be ineligible to participate in the study per investigator's judgment due to other reasons including the laboratory test results
    15. History of drug abuse or positive urine drug screen results

<Hemophilia patients>

  • Inclusion criteria

    1. Male hemophilia A or B patients aged 19-60 years (both inclusive) at screening
    2. ≥50 kg in weight with calculated BMI between 18.5 and 29.9 kg/m2
    3. Agree to use medically acceptable adequate dual contraceptive methods (condom, vasectomy, spermicide, oral contraceptives, intrauterine device, and complete sexual abstinence, etc.) and not to donate sperm until 60 days after administration of the investigational product
    4. Voluntarily decided to participate in the study and provided written consent to follow precautions after receiving a detailed explanation on this study and fully understanding the information
  • Exclusion criteria

    1. Symptoms of acute disease within 28 days of investigational product administration or any surgery planned during the study period
    2. Medical history that may affect absorption, distribution, metabolism and excretion of drugs
    3. Clinically significant active chronic disease
    4. Clinically significant allergic disease (however, mild allergic rhinitis or allergic dermatitis not requiring any medication is allowed) or history of any anaphylactic reaction
    5. Patients having current human factor VIII or IX with an inhibitor titer of >5 Bethesda units or patients requiring treatment with bypassing agent
    6. Patients who has a history of confirmed human factor VIII or IX with an inhibitor titer of >5 Bethesda units at any time
    7. History of ≥6 bleeding episodes despite temporary bypassing agent administered for 24 weeks before screening, or ≥2 bleeding episodes despite the bypassing agent administered prophylactically
    8. Received factor VIII or factor IX within 48 hours prior to administration of the investigational product
    9. Hemostatic agent, etc. prescribed to control bleeding within 5 days prior to administration of the investigational product
    10. Immune tolerance induction prescribed within 30 days prior to administration of the investigational product
    11. Currently using systemic immunomodulator (e.g., interferon or rituximab)
    12. Be at risk of thrombotic microangiopathy per investigator's judgment or have related medical history or family history
    13. Congenital or acquired anticoagulant disorders other than hemophilia A or B, or conditions of other diseases that increase the risk of bleeding or thrombus (e.g., autoimmune disease)
    14. Any of the following results from laboratory tests: 1) AST (sGOT) or ALT (sGPT) >3 x UNL 2) Hb < 9.0 g/dL 3) Absolute Neutrophil Count < 1500 mm2 4) Platelet count < 100 x 103 mm2 5) Have hepatitis B (HBs Ag positive) or C (anti-HCV positive), or have HIV positive test result 6) Creatinine clearance ≤80 mL/min (calculated by the Cockcroft-Gault formula)
    15. Cannot have standard meals provided at the hospital
    16. Participated in another clinical trial within 90 days of investigational product administration
    17. Individuals who consume caffeine (caffeine >5 cups/day) or alcohol (alcohol >30 g/day) continuously, who cannot abstain from drinking during the study, or heavy smoker (>10 cigarettes/day)
    18. Determined to be ineligible to participate in the study per investigator's judgment due to other reasons including the laboratory test results
    19. History of drug abuse or positive urine drug screen results

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03855696


Locations
Layout table for location information
Korea, Republic of
Yonsei Cancer Center, Yonsei University Severance Hospital
Seoul, Korea, Republic of, 120-752
Korea University Anam Hospital
Seoul, Korea, Republic of
Sponsors and Collaborators
Green Cross Corporation
Dream CIS, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Ji-Young Park, MD Korea University Anam Hospital
Layout table for additonal information
Responsible Party: Green Cross Corporation
ClinicalTrials.gov Identifier: NCT03855696    
Other Study ID Numbers: MG1113_P1
First Posted: February 27, 2019    Key Record Dates
Last Update Posted: October 26, 2021
Last Verified: October 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Green Cross Corporation:
MG1113
Hemophilia
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemophilia A
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn